Kyle Fraser

2.6k total citations
28 papers, 1.5k citations indexed

About

Kyle Fraser is a scholar working on Molecular Biology, Neurology and Physiology. According to data from OpenAlex, Kyle Fraser has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Neurology and 9 papers in Physiology. Recurrent topics in Kyle Fraser's work include Parkinson's Disease Mechanisms and Treatments (13 papers), Alzheimer's disease research and treatments (6 papers) and Extracellular vesicles in disease (5 papers). Kyle Fraser is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (13 papers), Alzheimer's disease research and treatments (6 papers) and Extracellular vesicles in disease (5 papers). Kyle Fraser collaborates with scholars based in United States, Canada and New Zealand. Kyle Fraser's co-authors include Andrew B. West, Hakho Lee, Ralph Weissleder, Xandra O. Breakefield, E. Antonio Chiocca, Laura A. Volpicelli‐Daley, Kyungheon Lee, Hisham Abdelmotilib, Leonora Balaj and Bassel Ghaddar and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and ACS Nano.

In The Last Decade

Kyle Fraser

24 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle Fraser United States 14 885 650 307 289 239 28 1.5k
Sabrina M. Heman-Ackah United States 13 742 0.8× 314 0.5× 199 0.6× 144 0.5× 173 0.7× 19 1.1k
Alwin Kamermans Netherlands 19 881 1.0× 131 0.2× 443 1.4× 206 0.7× 116 0.5× 27 1.6k
Maurizio Romano Italy 25 1.5k 1.7× 1.2k 1.9× 152 0.5× 354 1.2× 168 0.7× 78 2.6k
Dirk Fitzner Germany 15 1.2k 1.4× 212 0.3× 486 1.6× 272 0.9× 226 0.9× 32 2.2k
Ludovic Collin Switzerland 13 701 0.8× 136 0.2× 75 0.2× 437 1.5× 224 0.9× 27 1.6k
Chengyu Zou China 17 788 0.9× 144 0.2× 148 0.5× 407 1.4× 246 1.0× 25 1.6k
Bill Hendey United States 16 628 0.7× 277 0.4× 116 0.4× 273 0.9× 257 1.1× 23 1.6k
Mathilde Chivet France 11 1.2k 1.3× 102 0.2× 575 1.9× 89 0.3× 163 0.7× 12 1.3k
Dominik Fröhlich Australia 14 1.6k 1.9× 112 0.2× 788 2.6× 110 0.4× 185 0.8× 19 2.1k
Carlo Rinaldi Italy 21 1.2k 1.3× 306 0.5× 176 0.6× 93 0.3× 533 2.2× 47 1.7k

Countries citing papers authored by Kyle Fraser

Since Specialization
Citations

This map shows the geographic impact of Kyle Fraser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle Fraser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle Fraser more than expected).

Fields of papers citing papers by Kyle Fraser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle Fraser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle Fraser. The network helps show where Kyle Fraser may publish in the future.

Co-authorship network of co-authors of Kyle Fraser

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle Fraser. A scholar is included among the top collaborators of Kyle Fraser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle Fraser. Kyle Fraser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hauser, Robert A., Lorraine V. Kalia, J. Timothy Greenamyre, et al.. (2025). Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial. Parkinsonism & Related Disorders. 134. 107607–107607.
2.
Droby, Amgad, Dikla Atias, Kyle Fraser, et al.. (2025). Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients. npj Parkinson s Disease. 11(1). 7–7. 4 indexed citations
3.
Lang, Anthony E., Robert A. Hauser, Lorraine V. Kalia, et al.. (2025). LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease. Movement Disorders. 41(2). 297–314.
4.
Liu, Yuting, Minhua Yang, Kyle Fraser, et al.. (2024). Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100003–100003. 3 indexed citations
5.
Chen, Tianle, R. Matthew Hutchison, Philip H. Montenigro, et al.. (2024). A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(5). 1228–1240. 3 indexed citations
6.
Chen, Dan, Melissa M. Cadelis, Kyle Fraser, et al.. (2023). α,ω-Diacyl-Substituted Analogues of Natural and Unnatural Polyamines: Identification of Potent Bactericides That Selectively Target Bacterial Membranes. International Journal of Molecular Sciences. 24(6). 5882–5882. 8 indexed citations
7.
Vanbrabant, Jeroen, Steffi De Meyer, Carrie E. Rubel, et al.. (2023). Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays. Alzheimer s & Dementia. 19(S15). 1 indexed citations
8.
Vanbrabant, Jeroen, Sherif Bayoumy, Inge M.W. Verberk, et al.. (2023). Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217. Alzheimer s & Dementia. 19(S24). 2 indexed citations
9.
Cadelis, Melissa M., Dan Chen, Kyle Fraser, et al.. (2023). Investigation of Naphthyl–Polyamine Conjugates as Antimicrobials and Antibiotic Enhancers. Antibiotics. 12(6). 1014–1014. 1 indexed citations
10.
Cadelis, Melissa M., Ji Soo Kim, Kyle Fraser, et al.. (2023). Exploration of Bis-Cinnamido-Polyamines as Intrinsic Antimicrobial Agents and Antibiotic Enhancers. Biomolecules. 13(7). 1087–1087.
11.
Toomey, Christopher B., Kyle Fraser, John Thorson, Michael H. Goldbaum, & Jonathan H. Lin. (2019). GNAQ and PMS1 Mutations Associated with Uveal Melanoma, Ocular Surface Melanosis, and Nevus of Ota. Ocular Oncology and Pathology. 5(4). 267–272. 7 indexed citations
12.
Navarrete-Perea, José, Ala Jo, Simona Cristea, et al.. (2019). Physical and Molecular Landscapes of Mouse Glioma Extracellular Vesicles Define Heterogeneity. Cell Reports. 27(13). 3972–3987.e6. 54 indexed citations
13.
Abdelmotilib, Hisham, Vedad Delic, Zhiyong Liu, et al.. (2017). α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. Neurobiology of Disease. 105. 84–98. 120 indexed citations
14.
Park, Jongmin, Sangmoo Jeong, Ahmed T. Kurdi, et al.. (2017). Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant Rejection. ACS Nano. 11(11). 11041–11046. 112 indexed citations
15.
Volpicelli‐Daley, Laura A., Hisham Abdelmotilib, Zhiyong Liu, et al.. (2016). G2019S-LRRK2 Expression Augments  -Synuclein Sequestration into Inclusions in Neurons. Journal of Neuroscience. 36(28). 7415–7427. 141 indexed citations
16.
Fraser, Kyle, et al.. (2016). Ser(P)‐1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders. 31(10). 1543–1550. 144 indexed citations
17.
Alcalay, Roy N., Kyle Fraser, & Andrew B. West. (2015). Phosphorylated pS1292 LRRK2 to Total LRRK2 Concentration Ratio in Urine Exosomes Distinguishes LRRK2-PD and Idiopathic PD (S7.002). Neurology. 84(14_supplement). 2 indexed citations
18.
Szul, Tomasz, Preston E. Bratcher, Kyle Fraser, et al.. (2015). Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. American Journal of Respiratory Cell and Molecular Biology. 54(3). 359–369. 55 indexed citations
19.
Daher, João Paulo Lima, Hisham Abdelmotilib, Xianzhen Hu, et al.. (2015). Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. Journal of Biological Chemistry. 290(32). 19433–19444. 161 indexed citations
20.
Curtis, Luke, Vikki Garrick, Paraic McGrogan, et al.. (2013). N003 Practicalities of varicella screening and vaccination in the paediatric inflammatory bowel disease (IBD) patients. Journal of Crohn s and Colitis. 7. S297–S297. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabrina M. Heman-Ackah Breakdown of academic impact, for papers by Alwin Kamermans Breakdown of academic impact, for papers by Maurizio Romano Breakdown of academic impact, for papers by Dirk Fitzner Breakdown of academic impact, for papers by Ludovic Collin Breakdown of academic impact, for papers by Chengyu Zou Breakdown of academic impact, for papers by Bill Hendey Breakdown of academic impact, for papers by Mathilde Chivet Breakdown of academic impact, for papers by Dominik Fröhlich Breakdown of academic impact, for papers by Carlo Rinaldi
Rankless by CCL
2026